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Prevalence of Self-Reported Obesity Among U.S. 
Adults by State and Territory, BRFSS, 2014
¶ Prevalence estimates reflect BRFSS methodological changes started in 2011. These estimates should not be 
compared to prevalence estimates before 2011.
*Sample size <50 or the relative standard error (dividing the standard error by the 
prevalence) ≥ 30%.
Within Subsets of Patients with Overweight 
and/or Obesity
Deranged endocrine and 
immune responses 
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• Congestive heart failure and cor pulmonale
• Varicose veins
• Thromboembolic events (i.e., pulmonary embolus, stroke, etc.)
• Hypertension (i.e., compression of kidney)
Pulmonary
• Dyspnea
• Obstructive sleep apnea 
• Hypoventilation syndrome
• Pickwickian syndrome 
• Asthma
Neurologic
• Intracranial hypertension (pseudotumor cerebri) due to increased intra-
abdominal pressure, sleep apnea, etc. 
• Stroke (see “cardiovascular”)







• Osteoarthritis (e.g. knees, 
hips) 
• Low back pain 
• Myalgias







• Stria distensae (skin 
stretch marks)
• Stasis pigmentation 
• Venous stasis ulcers 
• Cellulitis 
• Skin tags
• Intertrigo (i.e. bacterial, 









• Adipocyte organelle dysfunction (endoplasmic reticulum, 
mitochondria, etc.)
• Increased circulating free fatty acids
• Pathogenic adipose tissue endocrine responses 
• Pathogenic adipose tissue immune responses
• Pathogenic consequences to other body organs such as 
fatty liver, vasculopathies (endothelial dysfunction, 
atherosclerosis, hypercoagulation), etc. 
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Adiposopathy (Sick Fat Disease) 
• Adipocyte hypertrophy 
• Increased visceral, pericardial, perivascular, and other peri-
organ adiposity 
• Growth of adipose tissue beyond vascular supply
• Increased adipose tissue immune cells
• “Ectopic” fat deposition in other body organs (liver, muscle, 




Adiposopathy (Sick Fat Disease) 
Adiposopathy most often results in metabolic disease when 
accompanied by:
• Dysfunction other body organ
• Limitations in the metabolic “flexibility” of other body organs
Metabolic health is dependent upon the interactions or 









• Other body organs 13
Other Body Organs
Reference/s: [4] [6] [19] [20]       
• High blood glucose (prediabetes
mellitus, type 2 diabetes mellitus)
• High blood pressure
• Metabolic syndrome
• Adiposopathic dyslipidemia
‒ Increased triglyceride levels
‒ Decreased high-density 
lipoprotein cholesterol levels
‒ Increased atherogenic particle 
number (increased 
apolipoprotein B)
‒ Increased proportion of small, 
dense, low-density lipoprotein 
particles
‒ Increased triglyceride-rich 
lipoproteins
‒ Increased lipoprotein-remnant 
lipoproteins
• Insulin resistance
• Hepatosteatosis (fatty liver)






• Neuropsychiatric diseases (such as 
worsening depression due to 
adiposopathic immune and 
endocrine responses)
• Asthma (due to adiposopathic
immune and endocrine responses)









































































































































































































































































































































































A surgical procedure where an adjustable band is placed around the upper 
stomach creating a small pouch. The band diameter is adjustable through 






A surgical procedure wherein the stomach is reduced to about 25 percent of its original 
size by the surgical removal of a large portion of the stomach along the greater 






































































A surgical procedure wherein the stomach is divided into a large residual 
section and a smaller section (pouch) that is attached to a limb of the small 
intestine at variable distances from the first part of the small intestine, largely 

































































Comparison of Outcomes for Bariatric Surgical Procedures
Outcome Overall Sleeve 
gastrectomy
RYGB
Excess body weight lost (%) median*
1 to 2 years 60 to 70 33 to 85 48 to 85
3 to 6 years 50 to 60 46 to 66 53 to 77
7 to 10 years 50 NA 25 to 68
Remission of diabetes 
mellitus
< 1 year 80 56 to 68 56 to 84
1 to 3 years 72 80 46 to 81
15 years 30 NA NA
Mortality
 30 days (%) 0.08 0.296 0.20 to 0.50
> 30 days (%) 0.31 0.11-0.34 0.14-0.21
7-15  years 30 to 40% lower than those not having surgery
NA = not available












































Identify and Manage Concomitant 












































Identify and Manage Concomitant 



























Identify and Manage Concomitant 
Pharmacotherapy That Might Alter Body Weight
Reference/s: [18] [57] [73] [74] [75] [76]       
Identify and Manage Concomitant 






























Identify and Manage Concomitant 






































‒ Adiposopathy or sick fat disease (SFD)
‒ Fat mass disease (FMD)
• Facilitate management of eating behavior 
• Slow progression of weight gain/regain
• Improve the health, quality of life, and body weight of 
the patient with overweight or obesity
Adjunct to nutritional, physical activity, and behavioral therapies
Reference/s: [55] [159]       
Pathologic Metabolic and/or Fat Mass 
Consequences of Increased Body Fat
• 5-10 percent weight loss may improve adipocyte and 
adipose tissue metabolic and immune function
– 5-10 percent weight loss may improve metabolic disease 
• 5-10 percent weight loss may improve abnormal and 
pathologic physical and mechanical forces 





















































































































Orlistat (Xenical) Pancreatic lipase inhibitor 120 mg orally with each 
meal containing fat
Not addressed in label

















































































































































Caution Contraindications Side Effects
Medications Approved for Chronic Weight Management
71
Eat Fewer Calories than you Burn = Lose Weight
Simple?
Obesity
pages S1‐S26, 7 JUL 2015 DOI: 10.1002/oby.21140
http://onlinelibrary.wiley.com/doi/10.1002/oby.21140/full#oby21140‐fig‐0004
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25
Please Respond…People can be addicted to 
food, just as others are addicted to drugs, and 
these people usually become obese.
A. Strongly Disagree
B. Disagree
C. Somewhat Disagree
D. Neutral
E. Somewhat Agree
F. Agree
G. Strongly Agree
73
Weight Bias
• We all have bias
• First, we must recognize it
74
Which surgical procedure for weight 
loss is performed most often in the US 
today?
A. Gastric banding
B. Sleeve gastrectomy
C. Roux‐en‐Y gastric 
bypass
D. Revision
75
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Patients who have had a weight loss 
surgery procedure should not take 
NSAIDS.
A. True
B. False
76
Which of the following weight loss 
medications is not approved for long 
term use?
A. phentermine 
ER/topirimate ER 
(Qsymia)
B. lorcaserin (Belviq)
C. liraglutide (Saxenda)
D. phentermine 
(Adipex)
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Questions?
Robin.Schroeder@lvhn.org
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